<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ARTENIMOL WITH PIPERAQUINE PHOSPHATE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ARTENIMOL WITH PIPERAQUINE PHOSPHATE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of uncomplicated falciparum malaria</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight 36&#8211;74 kg)</strong><br/>
                3 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course.</li>
              <li class="dose adult"><strong>For adults (body-weight 75&#8211;99 kg)</strong><br/>
                4 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course.</li>
              <li class="dose child"><strong>For children 6 months&#8211;17 years (body-weight 7&#8211;12 kg)</strong><br/>
                0.5 tablet once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course.</li>
              <li class="dose child"><strong>For children 6 months&#8211;17 years (body-weight 13&#8211;23 kg)</strong><br/>
                1 tablet once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course.</li>
              <li class="dose child"><strong>For children 6 months&#8211;17 years (body-weight 24&#8211;35 kg)</strong><br/>
                2 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course.</li>
              <li class="dose child"><strong>For children 6 months&#8211;17 years (body-weight 36&#8211;74 kg)</strong><br/>
                3 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course.</li>
              <li class="dose child"><strong>For children 6 months&#8211;17 years (body-weight 75&#8211;100 kg)</strong><br/>
                4 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Teratogenic in <i>animal</i> studies&#8212;manufacturer advises use only if other antimalarials cannot be used.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>No information available in moderate to severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>No information available in moderate to severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Acute myocardial infarction</li>
            <li>bradycardia</li>
            <li>congenital long QT syndrome</li>
            <li>electrolyte disturbances</li>
            <li>family history of sudden death</li>
            <li>heart failure with reduced left ventricular ejection fraction</li>
            <li>history of symptomatic arrhythmias</li>
            <li>left ventricular hypertrophy</li>
            <li>risk factors for QT interval prolongation</li>
            <li>severe hypertension</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain in children, anaemia, blood disorders in children, conjunctivitis in children, cough in children, diarrhoea in children, headache in adults, irregular heart rate in children, leucopenia in children, malaise, QT interval prolonged, rash in children, tachycardia in adults, thrombocytopenia in children, vomiting in children,
              </p>
              <p>
                <strong>uncommon:</strong> Abdominal pain in adults, acanthosis in children, anorexia in adults, arrhythmias, arthralgia, bradycardia in adults, convulsions, cough in adults, diarrhoea in adults, dizziness in adults, headache in children, heart murmur in children, hepatitis, hepatomegaly, influenza-like symptoms, jaundice in children, myalgia in adults, nausea, pruritus in adults, stomatitis in children, vomiting in adults,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Tablets to be taken at least 3 hours before and at least 3 hours after food.</p><p>Tablets may be crushed and mixed with water immediately before administration.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patients or carers should be given advice on how to administer tablets containing piperaquine phosphate with artenimol.</p>
            </section>
      </section>





      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Obtain ECG as soon as possible after starting treatment then continue monitoring in those taking medicines that increase plasma-piperaquine concentration, in children who are vomiting, in females, or in the elderly.</p><p>Consider obtaining ECG in all patients before third dose and 4&#8211;6 hours after third dose.</p><p>If QT<sub>C</sub> interval more than 500 milliseconds, discontinue treatment and monitor ECG for a further 24&#8211;48 hours.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ARTENIMOL WITH PIPERAQUINE PHOSPHATE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76518"><a href="../medicinalForm/PHP76518.html" data-target="#PHP76518" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
